Brandon takes an analytical, problem-solving approach to addressing the largest culprits in today's healthcare challenges. From healthy living and effective coping skills to medical compliance, much of our healthcare woes are the result of individual behaviors. When founding 2Morrow, he saw the potential for the omnipresent smartphone and its rich technology stack to change how healthcare is delivered. As a developer, technology leader and early innovator in habit formation, Brandon has broad experience including the highly regulated medical device world, applied machine-learning and the power of technology and data to both inform organizations and influence individual behaviors. With the smartphone, he saw the potential to expand the reach of healthcare by putting these powerful tools directly into the hands of patients and the public. 2Morrow is an evidence-based, digital therapeutic company focused on behavior modification.

Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.

Melinda Decker is a passionate leader with a rare mix of both commercial and R&D expertise, developed over nearly 20 years in the pharmaceutical-biotech industry. She has broad therapeutic experience with biologic, small molecule and digital health products, across both specialty and primary care, and with both global and local markets. She currently is the Oncology TA Head for Intelligent Pharmaceuticals, AstraZeneca’s digital therapeutics team, focused on improving patient outcomes through digital health. In this role, she works to integrate medicines with technology such as connected devices, sensors, and smart packaging across the entire development cycle of launched, pre-launched and pipeline products. She holds an MS in Biochemical Engineering and an MBA in Finance and Marketing.

Joel serves as Chief Commercial Officer for Click Therapeutics. Click develops software as prescription medical treatments to improve the lives of patients throughout the world.

For over 25 years Joel has helped payers, employers, providers and suppliers achieve better patient outcomes at a lower cost of care using new health technology. Helping to lead the charge for healthcare innovation, Joel will share how employers, insurers, and other healthcare payers are adopting Click’s clinically-validated digital therapeutics as key components to population health strategies.

While at Johnson & Johnson as Director of Payer Relations and with Walgreens as Vice President of Market Development Joel initiated pay for performance and shared savings models of value-based purchasing with payers and health systems. Joel also led commercial efforts with Sanofi Aventis to help providers contain the exploding costs associated with chronic conditions such as diabetes and cardiovascular disease.

Joel graduated from DePaul University in Chicago and later completed a Fellowship in healthcare leadership with the Washington DC based Advisory Board Company.

Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City, MO, focused on healthcare entrepreneurship. Prior to that, he completed his graduate work at Yale University in the Departments of Pharmacology and Molecular Biophysics & Biochemistry, focusing on structure-based drug design, where he led a research project that identified two novel chemical scaffolds as proof-of-concept compounds for novel therapy. Eddie received his B.S. in Biochemistry from Providence College, and his M.Phil. and Ph.D. from Yale University.

Debra is founding CEO of Palo Alto Health Sciences, a digital therapeutic company providing evidence-
based, at-home, drug-free solutions in behavioral health. Freespira® is an FDA-cleared treatment for
panic disorder, panic attacks and symptoms of panic.

Debra has broad operational and leadership experience in start- ups as well as large corporations. Prior to PAHS, Debra worked with a Bay Area incubator to develop a women’s health product, was founding CEO of Novasys Medical, and was VP/GM of a Division of Tyco, inc. (Mallinckrodt, Nellcor).

Debra holds an MBA and R.R.T credentials. She has been a guest entrepreneur for 5 years as part of a Harvard Business School case study and supports entrepreneurs through her work with Astia and with CSweetner as a mentor to female executives.

Edward Cox was appointed as the new Chairman of the Board and the Chief Executive Officer of Dthera in connection with the closing of the EveryStory Transaction. Mr. Cox also continues to serve as EveryStory’s President and Chief Executive Officer and Chairman and a member of EveryStory’s Board of Directors, positions he has held since February 6, 2015. Prior to that, he served as a Vice President and Executive Officer of Apricus Biosciences, Inc., a publicly traded company, since December 2009, in roles leading Commercial Development, Business Development, Investor Relations, and Corporate Development. Mr. Cox holds a Master of Science in Management degree from the Warrington College of Business Administration at the University of Florida.

Bakul Patel is Associate Director for Digital Health, at the Center for Devices and Radiological Health (CDRH), at the Food and Drug Administration (FDA). Mr. Patel leads regulatory policy and scientific efforts at the Center in areas related to emerging and converging areas of medical devices, wireless and information technology. This includes responsibilities for mobile health, health information technology, cyber security, medical device interoperability, and medical device software.

Mr. Patel is the FDA liaison between the Federal Communications Commission (FCC) and the Office of the National Coordinator (ONC). Since its inception in 2013, Bakul chairs the International Medical Device Regulators Forum (IMDRF) “software as a medical device” working group, a global harmonization effort.

Before joining FDA, Mr. Patel held key leadership positions working in the telecommunications industry, semiconductor capital equipment industry, wireless industry and information technology industry. His experience includes Lean Six Sigma, creating long and short-term strategy, influencing organizational change, modernizing government systems, and delivering high technology products and services in fast-paced, technology-intensive organizations. Mr. Patel earned an MS in Electronic Systems Engineering from the University of Regina, Canada, and an MBA in International Business from The Johns Hopkins University.

As CEO, Kevin has led the WellDoc® team in the successful launch and continued development of the digital therapeutic for people living with type 2 diabetes, BlueStar®. Under his leadership, WellDoc has expanded its suite of BlueStar products to include: BlueStar® Rx, BlueStar® and BlueStar® C. Kevin oversees all WellDoc business related to enterprise strategy and has engineered an innovative commercial approach to position BlueStar in the marketplace to attract key investors and partnerships that include, Johnson & Johnson, Samsung and Merck GHI.

Joris van Dam is a Digital Health intrapreneur with 15 years’ experience in Pharmaceutical Research & Development, focusing on the innovative use of digital technologies to improve and transform therapeutic innovation, patient engagement, and clinical trials operations. Joris is currently leading the Digital Therapeutics initiative at Novartis Institutes for BioMedical Research, including its collaboration with Pear Therapeutics on the development of therapies in schizophrenia and multiple sclerosis.

Prior to that, Joris launched a number of digital health innovation initiatives at Novartis, including the launch of the Trials of the Future program, the Patients-2-Trials Consortium (a pharma consortium project to facilitate clinical research navigation for patients), the Clinical Research Collaboration with Walgreens (running interventional clinical trials at local Walgreens Healthcare clinics), TriNetX (a platform for using electronic medical records for study planning and design), CentrosHealth (a platform for patient engagement Apps in clinical trials), and a mobile platform for bedside data collection for clinical trials in Africa.

Prior to joining Novartis, Joris spent 7 years at Janssen, where a.o. he worked in partnership with the Bill and Melinda Gates Foundation to launch a mobile health platform for improving treatment of HIV patients in various regions across India, and led Janssen’s participation to the EHR4CR program at the EU’s Innovative Medicines Initiative (IMI). Prior to joining pharmaceutical research and development, Joris spent 7 years in consulting across industries and across Europe. Joris holds a PhD in Artificial Intelligence from the University of Amsterdam.

LTP is a $313M growth equity fund investing exclusively in digital health and healthcare services. Sasha K. Said is a founding member of the LTP investment team where she sources and structures deals; provides representation for LTP on the Board of Directors; and provides strategic and tactical support to portfolio companies. She has 10 years of investing experience across asset classes, 4 of which were spent with Waypoint Capital, the multi-billion dollar investment group that represents the Bertarelli family. While there she helped launch a $2B life science fund, Gurnet Point Capital, now managed by Chris Viehbacher (former CEO of Sanofi), as well as built their corporate venture group with a strategy in digital health. Prior to Waypoint, Sasha was a Global Long/Short Public Equity and Private Equity Analyst at Water Asset Management, a global hedge fund in New York City.

Sasha serves as a Board Observer on the Boards of Vera Whole Health and Health Catalyst and is a Board Member of Rimedio, an early stage pharma services company. She is founder of Breaking7% (B7), a group of 122 women (51% senior/ 49% junior) in deal making roles in Boston who meet monthly to exchange deals and contacts. She is also an Advisor to Pulse companies, Massachusetts’ digital health accelerator.

Frank is Chief Commercial Officer at Neurometrix where he is leading the creation of new therapeutic category with the launch of Quell™ Wearable Pain Relief Technology, an FDA cleared, 100% drug free alternative for managing chronic pain. Quell was winner of the 2016 SXSW Innovation Award for Wearable Technology one of four health and fitness finalist for the Best of CES. After a successful crowdfunding campaign on Indiegogo, Quell is now available online and through major US retailers including Amazon, CVS, Best Buy and others. Quell has been covered extensively in national media including Good Morning America, CBS News, Forbes, Fortune, Wired and Men’s Health.

Frank has over 20 years of experience building successful, high-growth consumer health and technology brands at Philips and Johnson & Johnson, launching over 50 new products and leading global expansion of Sonicare. He has a passion for innovation in digital health.

Gregory Dodell, MD FACE is a board-certified endocrinologist. He received his medical degree from Albany Medical College. He completed his internal medicine and endocrinology Fellowship at St. Luke’s-Roosevelt Hospital Center, affiliated with Columbia University. He is an Assistant Clinical Professor of Medicine, Endocrinology, Diabetes and Bone Disease at the Icahn School of Medicine at Mount Sinai. He is the President of Central Park Endocrinology, PC.

Seth Feuerstein is the chief medical officer of medical and digital innovation at Magellan Healthcare. In this role, he leads the development of effective business and clinical programs that leverage technology in several areas. Feuerstein, a psychiatrist by training, most recently developed Cobalt, a virtual therapeutic program which addresses 90 percent of behavioral health disorders. Feuerstein developed this virtual care platform to achieve better health, better care, and lower costs. With its acquisition of Cobalt, Magellan helps clients deliver online cognitive behavioral therapy to address problems such as anxiety, insomnia, depression, OCD and substance abuse.

Ruchita Sinha is Sr. Director of Investments at Sanofi Ventures where she invests in biopharma and digital health opportunities. She led Sanofi’s investments in Inozyme, Omada Health, Evidation Health, Curisium, and also manages investments in Science 37 and Common Sensing. Prior to Sanofi, Ruchita was at GE Ventures, where she served as a board observer for HeadSense Medical and Caremerge and managed GE’s investments in CheckCap (Nasdaq: CHEKU) and HeartFlow. She also managed GE’s seed-stage portfolio of digital health investments in partnership with StartUp Health.

Ruchita has more than 15 years of healthcare experience in pharma, biotech, medical devices, and digital health. Previously, Ruchita was at Pfizer’s Strategy, BD, & Portfolio Management group, and a management consultant with LEK Consulting. Ruchita started her career with Maxygen, an early stage biotech company. She holds an MBA from the University of Chicago, an MS in Cellular and Molecular Biology from the University of Wisconsin-Madison, and a BS in Biochemistry from Mount Holyoke College.

Kevin is the co-founder and CEO of Better Therapeutics, a company developing prescription digital therapeutics for treating lifestyle-related diseases. He has been an active entrepreneur for more than 20 years, building and leading multiple transformative companies at the intersection of traditional consumer and healthcare industries. Earlier in his career, he was an executive with Procter & Gamble and PepsiCo, where he experienced first-hand that corporate food interests are not aligned with the best interests of individual health. He holds a B.S. in chemical engineering from the University of Pennsylvania. Following graduation, he served peacetime and combat assignments as an officer in the U.S. Army Rangers.

Dr. Salisbury is Executive Vice President of Crisis and Behavioral Health Technologies and Strategic Planning at the Mental Health Association of New York City and has over 25 years of experience as a mental health clinician, administrator, educator, consultant and policymaker focusing on behavioral health issues. She has been instrumental in building MHA-NYC’s diverse portfolio of innovative programs and services, including workplace wellness programs, family support programs, disaster mental health services, and technology assisted behavioral health services.

Dr. Salisbury received a Ph.D. in Counseling Psychology and Ed.D. in Educational Policy Studies from the University of Massachusetts at Amherst. She is Assistant Clinical Professor of Psychology in Psychiatry at Yale University School of Medicine.

David Amor is an FDA/ EU Quality/ regulatory expert focused on combination products and digital health. From NDAs and 505(b)(2)s to mobile app 510(k)s and Pre-INDs/ Q-subs, David has worked with over 45 medical device and pharmaceutical companies – large and small alike- supporting and/ or leading regulatory submissions and implementing quality management systems, including alignment of Agile-based SDLC programs to FDA and EU requirements. He co-founded RemindTrac in 2014 (www.remindtrac.com), a digital health company for chronic patients, that continues to pioneer mobile care management systems today, and sold his consulting firm Medgineering in 2016.

David has recently led QA/RA strategy groups at Teva within the Digital Health Group, particularly in development of Agile-based Quality Management Systems, was a Principal Consultant in the CP/DH (Combination Products, Digital Health) group at Qara Partners, and served as the in-house risk management subject matter expert at Abbott (St. Jude Medical). He has served as the Director or VP of Quality at other medical device start-ups including AdrenaCard, Calcula, Enspero Medical and various others, and led multiple organizations through 483 and Warning Letter remediation projects, namely associated with risk management and design history file deficiencies, including Pfizer (Hospira), MID, Boston Scientific and St. Jude Medical.

Believe Limited, a WEBBY-winning content agency. Patrick is the #1 social influencer in bleeding disorders and rare diseases and a leading expert in leveraging educational, narrative, podcast and documentary content to build deeply engaged, disease-specific audiences. Founding Board President, Entertainment to Affect Change (E2AC).

Kaia Health Inc. was founded with the aim to create evidence-based applications for self-management of chronic diseases to reflect the growing evidence of patient empowerment with effective therapies. Treatments which place patients in the driver’s seat of disease management and offer non-pharmacological alternatives are rapidly gaining importance in almost any chronic illness- from pain conditions to neurodegenerative diseases.

Kaia aims to create interdisciplinary digital approaches that empower patients to take control of the management of their diseases at low costs and to democratize access to required lifestyle changes following onset of a chronic disease. To achieve this, Kaia brings together experts in each of the medical fields in the creation of content and applications. This approach is paired with technological innovations to increase patient motivation, ensure correct exercise execution and monitor disease activity. Kaia’s first app democratizes the access to the multimodal back pain therapy. Pilot studies have consistently shown enduring pain reduction in users. This effect is currently being reproduced in RCTs. Kaia’s late stage pipeline ranges from COPD to osteoarthritis and Parkinson’s.

Konstantin is a serial entrepreneur. His last company foodora, a global food delivery company was sold to delivery hero in 2015. He now builds a digital therapeutics company called Kaia Health. He holds a dual Masters in Finance and Energy Systems from Columbia University and a Bachelor’s degree from Technical University.

John currently is an investor and active advisor to many early-stage companies, in areas ranging from virtual reality (VR) platforms and content publishers to digital health apps for diagnosing and treating cognitive conditions like ADHD. John was most recently the General Manager of Disney’s (DIS) mobile and social games division, where he launched many chart topping titles while handling the full P&L for this multi-hundred million dollar business. John brings a deep understanding of creating innovative consumer experiences, building brands and leveraging new and emerging platforms to JAZZ. He is a proven leader in consumer technology and digital media with a career spanning nearly 20 years of building, scaling and running high-growth companies of all sizes, from initial seed through to late stage.

Alex is a senior level global bio/pharmaceutical business leader with 27+ years of experience with large pharmaceutical, fully integrated biopharmaceutical and startup organizations. He has a proven record of building and leading business strategy and operations. In his career, Alex has driven enterprise value from portfolio strategy through to commercial launch. In previous roles, Alex has architected the structure and growth of several divisions at Biogen and helped to shape the emerging biosimilar market at Epirus Biopharmaceuticals. Alex has also worked in numerous commercial and operations roles at Genzyme, Astra Zeneca, Pfizer and Bristol-Myers Squibb.

Jo is fascinated by the convergence of mobile technology and behavioral science, especially surrounding the area of healthcare. At 2Morrow, Jo leads the research and program development efforts to make evidence-based behavior modifications programs more accessible by putting them directly in the hands of those who need them via their smartphones. Focused on drivers that affect chronic disease (i.e. smoking, weight, stress, chronic pain management), 2Morrow's evidence-based platform makes it easier and more convenient to include behavioral science into existing health care treatment plans. 2Morrow distributes programs distributed via employers, wellness platforms, health plans, providers and public health. Jo is a past ``40 under 40`` who started her career as a nurse and has worked in healthcare, education and technologies companies.

Eileen Rodgers is director of the VITAL program for Pittsburgh-based Highmark Health, a national health and wellness organization and America’s second largest integrated financing and system (IDFS) based on revenue.

Ms. Rodgers joined the Highmark Health innovation team in 2016 to lead the VITAL program, a test- and- learn platform that can help propel new health solutions into the marketplace by providing the ideal environment for producing evidence. As part of the VITAL team, Eileen is passionate about bringing the best health innovations to our customers and ensuring that Highmark Health is seen as a next- generation leader in transforming care.

An accomplished organizational leader, Ms. Rodgers has focused her career on championing new solutions and initiatives that can transform the way customers interact with the healthcare system. In her current role, she has the unique opportunity to lead a high-performing team devoted to launching test and learns which gather valuable evidence that can lead to reduced medical spend, improved quality outcomes, and enhanced patient access to new technologies. Prior to joining Highmark Health, Ms. Rodgers worked at Highmark BCBS. During her 17 year tenure, she developed a passion for affecting a return on health for our customers and in accelerating valuable new health care solutions through key leadership roles in health plan operations, product development, and innovation.

Ms. Rodgers earned a Bachelor of Arts in Communications and Psychology from the University of Pittsburgh.

Eileen lives in Pittsburgh with her husband, Rick, three daughters, and cuddly pooch. She enjoys spending time with them, traveling to new locations, riding the latest roller coasters, watching movies, being outdoors, and reading for relaxation.

Brent is the CEO and co-founder of Cognoa, an AI-based digital precision medicine behavioral health platform. Cognoais developing innovative digital diagnostics and digital therapeutics to change the standard of care for pediatric behavioral health and improve outcomes by enabling earlier diagnosis, treatment, and increased engagement. Brent has over 20 years industry experience working with diagnostics, therapeutics and digital consumer health. Prior to Cognoa, Brent was the co-founder and COO of WellnessFX, an award-winning digital health company that increased patient engagement by providing direct-to-consumer diagnostics and integrated telemedicine. Before working in digital health, Brent worked in product and commercial roles in Novartis, Nektar, Roche and Lily.

Jeff is a proven technology architect and innovator with extensive experience in pharmaceutical R&D, medical device, and commercial software development. Currently Jeff manages a global team responsible for web, mobile, healthcare technology, business intelligence, analytics, platform architectures, software design, and solution delivery. In addition, his team is responsible for understanding and applying emerging technology to J&J business problems that will move the company forward in its quest to improve outcomes for patients.

Everett is the Head of Market Access & Reimbursement with Pear Therapeutics, a digital therapeutics company located in Boston, Massachusetts. At Pear, Everett leads payer strategy and engagement, pricing, reimbursement, HEOR, and government affairs. In past roles he has led the launch readiness and market access and reimbursement commercialization of infused, oral, drug-device combination, and digital therapies, and he has extensive experience managing pricing, payer, and reimbursement diligence for in-licensing, out-licensing, and buy-outs.

Adam Kaufman is a health pioneer, having led the building of digital behavior change programs used by dozens of healthcare organizations and tens of thousands of consumers. A health economist, engineer and company executive, Adam speaks to audiences nationwide on the accelerating trend of chronic illness, its impact on lives and costs of care and proven approaches to arresting disease trajectories.
Recognized as a leader in patient engagement and population health, Canary Health works with health plans such as Kaiser Permanente, Humana, GEHA and Blue Shield of California to empower members to better health self-management.

Swatee Surve, Founder & CEO, is a leader who has developed and launched disruptive technology-based healthcare businesses for Microsoft, Nike, T-Mobile, Premera Blue Cross and Eastman Kodak. These commercialization projects led to several patents including Nike's first wearable technology patents. Surve has an MBA from the University of Chicago, an MSME in Biomechanics from Pennsylvania State University, and a BS in Bioengineering from the University of Illinois at Chicago. She has been featured in international, national, and regional media outlets including Huffington Post, International Business Times, NPR’s KUOW’s Morning Edition, APM: Marketplace, VentureBeat, Kauffman Foundation, and iMedicalapps.


Cris De Luca is currently the Global Head of Digital Innovation for Johnson & Johnson Innovation, based in Cambridge, Massachusetts. He is responsible for identifying and fostering transformational high-tech external innovation solutions across J&J’s Innovation Centers, JLABS incubators, and JJDC corp ventures supporting the Pharma, Consumer and Medical Device businesses. He formerly led Emerging Technology programs within research informatics at Novartis.

De Luca is most notably known for his role in the innovation economy since Co-Founding Ultra Light Startups, the oldest and largest startup-investor pitch accelerator in Boston and New York City with additional chapters in Silicon Valley and London. ULS accelerated 700+ bootstrapping startups with 26% having gone on to raise angel/venture funding, leading to several large-scale acquisitions by companies such as Apple, Trip Advisor, and Singapore Telecom.

Cris serves on the advisory boards of SXSW Health, AARP Health Innovation and VOICE Summit by Amazon Alexa. He holds a Masters in Computer Information Systems from Boston University and recognized as a 40 under 40 Healthcare Innovator by the Boston Business Journal and Medtech Boston.

Tim leads market research and strategy for Stella’s Innovation Lab, a small team that invests in and builds healthcare products and services. Stella is the parent company to a diverse set of health companies including Blue Cross Blue Shield of Minnesota, Further, Learn to Live, and Livio Health, which affords a unique opportunity to accelerate the growth of health innovations through these channels. Tim is an active advisor in the digital therapeutics space and brings a wealth of knowledge regarding market sizing & segmentation, payer value prop development and commercialization strategies. Prior to working at Stella, Tim worked as a MedTech consultant, advising start-ups and Fortune 500 companies on market opportunities, barriers to adoption, and growth strategies and holds a B.S. and Ph.D. in Biomedical Engineering.

Dr. Maricich leads the Clinical/Regulatory team at Pear Therapeutics as the Chief Medical Officer and Head of Clinical Development. He collaborates with the executive team on management and strategy. He leads and manages the clinical development programs from Discovery/TPP to Therapeutic, Translational, Clinical Development, through Regulatory submission and prosecution. He leads the team for Pear’s reSET clinical program, including the team and strategy for their De Novo Request/Submission of reSET to the FDA, which was cleared by the FDA as the first prescription digital therapeutic to treat disease. In addition to overseeing subsequent pipeline programs, including reSET-O (1st drug/software combination), Dr. Maricich leads Medical Affairs, responsible for successful coverage decisions and works closely with the Pear BD team on business development and biopharma deals and partnerships.

Jenn Millard works with clients to identify and source fit-for purpose Real-World Data, both from IQVIA and third-party data assets, and Evidence Network solutions to enable evidence generation through a combination of data, services and technology. She has over 15 years of experience in primary and secondary research across life sciences and healthcare organizations and over 10 years of experience with Real-World Data. Her therapy area expertise includes Neurology, Dermatology, Cardiovascular Diseases, Haemophilia, Kidney Disease, and Digital Therapeutics. She holds Bachelor of Science degrees in Marketing and Psychology from Pennsylvania State University and an M.B.A from Template University.

Steve joined MRx in 2010 and is currently the Vice President of Pharmacy Services and Clinical Strategy. He oversees the clinical account-facing staff (i.e. PAEs, or Pharmacist Account Executives), drug evaluation and policy development (e.g. P&T, Therapeutic Action Committee, or TAC), and clinical program development. Prior to this role, his area of focus was “traditional” (i.e. non-specialty) clinical program development and implementation, particularly within the STAR and HEDIS space. He had heavy involvement in the management of quality programs to improve performance of health plan customers in STAR and HEDIS measures.

Steve has been in the healthcare industry for more than 7 years. He began his career as a retail pharmacist and transitioned to managed care in early 2010. His main managed care experience began with MRx, developing carve-out formulary and clinical program strategy.

Steve earned a Doctor of Pharmacy from the University of Rhode Island. He also serves as Adjunct Clinical Assistant Professor of Pharmacy Practice at URI and mentors 6th-year pharmacy students as a preceptor. He is a Registered Pharmacist in the state of Rhode Island.

Marc Duey, Founder and President ProMetrics for over two decades, serves the decision support needs of specialty biopharma executives with a focus on patient-level data impacting prescription efficiency. ProMetrics’ proprietary technology platforms for data collection, aggregation, integration, analysis and reporting cost-effectively bring systems of record, information, and knowledge into systems of intelligence. ProMetrics has served over 150 clients, completed over 10,000 projects and helped in the launch of dozens of brands with sales in excess of a billion dollars.

Joe Glass, PhD, MSW, LICSW is an Assistant Investigator with Kaiser Permanente Washington Health Research Institute and an Affiliate Assistant Professor at the Department of Psychiatry and Behavioral Sciences of the School of Medicine at University of Washington. Dr. Glass was recently awarded a five-year career-development award from the National Institute of Health to study how to integrate digital treatments in healthcare settings. His research team is designing and testing strategies for implementing digital treatments for alcohol, opioid, and other substance use disorders in real-world primary care settings. He is known in his field for his work on brief interventions in healthcare settings. He is a licensed clinical social worker, and previously practiced at the US Department of Veterans Affairs in Ann Arbor, Michigan.

Jim O’Donoghue, President of S3 Connected Health, has 16 years’ experience in designing and delivering innovative connected health services and solutions. Having led the development and deployment of technology-enabled patient services for rare and chronic conditions that have been rolled out across 40 countries, Jim is focused on the future of digital patient services and the integration of solutions into clinical care pathways as we move towards Value-Based Care. An advocate of empowering patient self-management, Jim has overseen the design of the largest telehealth program in the UK and the largest chronic disease management program in Europe.

Brian Clancy is Co-Lead for AppScript, the world’s leading curation, prescribing, and studies platform for digital patient engagement tools. Prior to AppScript, Brian had a seven-year career as a strategy consultant to leading and emerging health technology and pharmaceutical companies. He is an author of various academic and industry publications on personalized medicine and digital health, including the recently published report by the IQVIA Institute for Human Data Science entitled ``The Growing Value of Digital Health.`` His research has been featured in The Economist, The Lancet, Tech Crunch, and Eric Topol's Twitter feed. He is an inventor in the field of app curation and a conference speaker on the topic of technical innovation in healthcare. Brian holds Bachelor of Science and Bachelor of Arts degrees in Molecular Genetics and Economics from the University of Rochester.

Kyle is an industry innovator focused on developing solutions and businesses at the intersection of healthcare delivery, research, and patients. He currently is Executive Director at ProMetrics where he leads the product strategy for the SPEED program.

He was a key leader in Real World Data access and post market digital health solutions at PAREXEL for over 10 years. He was an established innovation leader, where he led many high profile client-focused digital health strategies. These included the first direct-to-patient study with Pfizer, the Walgreens study with Novartis, and the largest global RWE respiratory study with AstraZeneca.

Most recently Kyle served as Vice President of HealthVerity, leading a novel effort to utilize a next generation healthcare data marketplace to create patient level journeys with RWD from medical claims, EHR, genomics, socioeconomic, pharmacies, and labs.

He has brought several novel digital health solutions to market and continues to serve as a key advisor for several industry initiatives fostering open collaboration and trust.

Jessica Perry, Associate Director, Patient Recruitment Strategy has worked in clinical research for over 15 years. She currently leads the development of innovative recruitment strategies for IQVIA Virtual Trials using her in-depth clinical trial and multi-therapeutic expertise. Her previous therapeutic experience includes ophthalmology, cardiovascular therapies, rare diseases, multiple sclerosis, depression, women’s health, pediatric medicine, and infectious disease. Ms. Perry has worked on phase II, III, & IV clinical trials and this experience spans the execution of clinical trials, from study start-up to project close-out and archival. Ms. Perry also has expert working knowledge of FDA regulations, ICH guidelines, Good Clinical Practices and Standard Operating Procedures.

Gordon Cummins strategizes to develop optimal evidence environments for real world evidence including data sources, partnerships, technology, and operational processes. He bring more than 20 year of experience in real world evidence and value development for all stakeholders. Gordon has also led digital engagements with patients and caregivers integrating in developmental value lifecycle. He is past co-chair for ISPOR special interest group for retrospective databases and have published numerous real world value articles across multiple therapeutic/condition areas. Gordon has a bachelors in mathematics/actuarial science and a masters in statistic from Missouri State University.

Jeffrey has over 10 years’ experience in healthcare services/operations, market access, reimbursement, and HEOR. Jeffrey has worked both on the industry and consulting side of pharmaceuticals, medical devices, and diagnostics. His previous experience includes global work in the US, EU, and select APAC markets, covering 30 different products. Most recently he served as the Value Development Lead for The Medicines Company and their surgery/perioperative products. He was responsible for a value and evidence based approach to access and commercialization. He graduated from Boston University with a Bachelor of Health Sciences, Master of Science in Physical Therapy, and a Master of Business Administration.